BlendNot ApprovedMixedVery Low confidenceSourced

KLOW blend

A four-component GHK-Cu, BPC-157, KPV and TB-500 research blend with no controlled human evidence for the combined formulation.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Community-reported schedule

Community-reported · not a validated schedule

Community dose schedule

A community KLOW blend (GLOW plus KPV) at 50/10/10/10 mg (80 mg total), reconstituted in one vial and dosed subcutaneously by its GHK-Cu content. Total blend mass shown per injection; community reports only, not a validated schedule.

Evidence source

Reported maximum quantity

GHK-Cu-based daily dose (forum)

Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.

Reported quantities by phase

Select a point for its calculation examples

Daily (GHK-Cu basis)
~3.2 mg total
50/10/10/10 mg blend (GHK-Cu / BPC-157 / TB-4 / KPV); ~3.2 mg total delivers ~2 mg GHK-Cu plus ~0.4-0.55 mg each of BPC-157, TB-4 and KPV. One report injects 4 mg of the mix nightly.

Vial-aware arithmetic

Reconstitution examples, up to 3 mL

Choose the vial quantity and BAC water first. The diagram and results below update for the selected ~3.2 mg total reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Vial quantity

Choose the quantity printed on the vial.

BAC water added

Use 1, 2 or 3 mL, or enter a custom volume up to 3 mL.

Open the full reverse calculator

Three millilitre research vial, diluent vial and capped U-100 syringe on an ink-blue surface — One small vial, one measured diluent volume and one U-100 scale. The arithmetic connects all three.

BAC water selected

3 mL

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.

U-100 draw12 U

20-30 U reference band

1 mL BAC

4 units

resulting U-100 draw

Concentration: 80 mg/mL
BAC added: 1 mL

2 mL BAC

8 units

resulting U-100 draw

Concentration: 40 mg/mL
BAC added: 2 mL

3 mL BAC

12 units

resulting U-100 draw

Concentration: 26.667 mg/mL
BAC added: 3 mL

Shown in the diagram. Closest of these examples to 25 units.

Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily

Third-party educational schedule for an 80 mg KLOW blend

Weeks 1-2 use 1.25 mg GHK-Cu plus 250 mcg each of BPC-157, KPV and TB-500 daily; weeks 3-4 double those amounts; weeks 5-8 use 3.75 mg plus 750 mcg each; weeks 9-12 return to the week 3-4 quantities

These quantities are calculated from the stated 50:10:10:10 blend ratio. No controlled human study validates the mixture or progression.

View source

Community GuideSubcutaneous in reportsUsually daily in reports

online research community KLOW reports

One frequently repeated 50:10:10:10 mg GHK-Cu, BPC-157, TB4 and KPV vial is divided into ten daily portions, yielding about 5 mg plus 1 mg of each other component per portion

Other reports use lower quantities and premixed vial ratios vary. No human study validates the combination, and occasional twice-daily use is an acute-pain anecdote; raw/peptide-education/pe-ghk-cu.md:4470-4473 and 5021-5037.

View source

Community GuideSubcutaneous in reportsUsually once daily; KPV sometimes as-needed

authenticated research-forum (Peppys) KLOW reports

KLOW is described as GLOW plus KPV - a single-vial 50:10:10:10 mg GHK-Cu, BPC-157, TB-4 and KPV blend (80 mg total) dosed subcutaneously by its GHK-Cu content, most often about 2 mg GHK-Cu once daily (roughly 3.2 mg total blend, carrying about 0.4-0.55 mg each of BPC-157, TB-4 and KPV); one report injects 4 mg of the mix nightly, and KPV is also run as-needed for pain

Forum provenance from an authenticated archive with usernames and post numbers omitted. An expert reply frames it as dosing it like GLOW, either replacing BPC-157 with KPV or adding a KPV vial; quantities and ratios conflict and headache reports prompt some to run GHK-Cu with KPV only. These quantities are community provenance, not a validated protocol.

View source

Evidence summary

A four-component GHK-Cu, BPC-157, KPV and TB-500 research blend with no controlled human evidence for the combined formulation.

Protocol basis

No matched clinical protocol was found for this named combination. Component literature is displayed only to explain why it cannot validate the blend.

Community provenance (Peppys)

An authenticated research-forum archive describes KLOW as GLOW plus KPV - a single-vial GHK-Cu, BPC-157, TB-4 and KPV blend, commonly at 50:10:10:10 mg, reconstituted together and dosed subcutaneously by its GHK-Cu content, most often around 2 mg of GHK-Cu once daily with the smaller components riding along at roughly half a milligram each. An expert reply frames it as dosing it like GLOW, either replacing BPC-157 with KPV or adding a KPV vial; some run KPV as-needed for pain, and headache reports lead others to keep only GHK-Cu with KPV. Reported quantities and ratios conflict, usernames and post numbers are omitted, and the figures are logged as community provenance without endorsement. The planner above reproduces the arithmetic of these reported quantities as a total blend mass; it does not validate them.

What remains uncertain

Compatibility, stability, combined pharmacology, systemic safety and clinically meaningful outcomes are unknown.

Warnings and contraindications

No controlled human study of the four-component blend was identified.

KPV human evidence concerns a related oral analogue rather than this mixture.

Adding components multiplies unresolved formulation, interaction and exposure questions.

KLOW is not a standardised formulation; channel and commercial component ratios differ.

Organised research bench with labelled storage tray, vial rack, notebook and thermometer — A clean workspace supports traceability. It does not establish sterility.

Shared across protocols

Supplies and general handling

Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.

Research vial

Select the labelled vial quantity used in the calculation.

View Peppys vial

Bacteriostatic water

Use only a diluent appropriate to the research method and formulation.

View Peppys BAC water

U-100 measuring syringe

Use a new sterile device for every entry. Source locally.

Source locally

Wipes and sharps container

Plan clean handling and immediate sharps disposal. Source locally.

Source locally

Storage follows the label

Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.

Use sterile equipment once

CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.

Stability is formulation-specific

Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.

General references: CDC injection safety, NHS medicine storage and DailyMed BAC water labelling.